Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments [Seeking Alpha]
Ocugen, Inc. (OCGN)
Company Research
Source: Seeking Alpha
FDA and EMA regulatory alignment enables a single U.S. trial to support both BLA and MAA filings for OCU410ST, expediting potential approvals. Interim data from GARDian3 is expected by mid-2026, with possible BLA submission for OCU410ST in 2027 if results are positive. Financial runway extends into Q2 2026; warrant exercises could provide an additional $30 million, but ongoing cash burn remains a key risk. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Nuttawan Jayawan/iStock via Getty Images The last time I spoke about Ocugen OCGN ) it was with respect to a Seeking Alpha article entitled " Ocugen: Two Gene Therapy Data Readouts In 2024 to Drive Value More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week fr
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]Seeking Alpha
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewswire
- Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]Yahoo! Finance
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial DataGlobeNewswire
OCGN
Earnings
- 8/1/25 - In-Line
OCGN
Sec Filings
- 1/15/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- OCGN's page on the SEC website